AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01116349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate and screws or nailing
Description: Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
Study NCT01116349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hanging Support System (HSS) brace
Description: Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
Study NCT04427228 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiosurgery Single Treatment
Description: Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
Study NCT00982137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus; Yellow fever virus
Description: Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
Study NCT03922503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)
Description: In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
Study NCT03922503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)
Description: After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
Study NCT02387398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Angiography
Description: Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
Study NCT02421432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Laparoscopy-assisted transanal total mesorectal excision
Study NCT03967652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nanomaterial-based sensors
Description: Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
Study NCT00649324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide Tablets 50 mg
Description: 50mg, single dose fasting
Study NCT00649324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide Tablets (50 mg
Description: 50mg, single dose fasting
Study NCT00025493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT04034485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: PCSK9 inhibitor
Study NCT04034485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab
Description: PCSK9 inhibitor
Study NCT00948701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Forward Together 2
Description: RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
Study NCT00948701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moving Forward Together 2
Description: RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
Study NCT01925105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Optimization of treatment
Description: Optimization of treatment of diseases and symptoms
Study NCT04427228 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery Three Treatments
Description: Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
Study NCT02379871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Supine mid-thoracic spinal manipulation to the T4/5 region
Study NCT02379871 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
Study NCT04177160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects sit still and listen to preferred music for 5 minutes.
Study NCT04177160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White noise
Description: Subjects sit still and listen to white noise for 5 minutes.
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
Study NCT02074397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distant extrafascial injection
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
Study NCT02074397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subfascial injection
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
Study NCT01337258 — intervention group
Intervention type: DRUG
Intervention: Dutasteride
Description: dutasteride 0.5mg daily.
Study NCT03756870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
Study NCT01337258 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Men taking placebo daily
Study NCT00424840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Description: Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2
Study NCT02932670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: costoclavicular nerve block
Description: ultrasound-guided costoclavicular nerve block
Study NCT02932670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: costoclavicular nerve block
Description: ultrasound-guided costoclavicular nerve block
Study NCT00003746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-chlorodeoxyadenosine (CDA) daily
Description: Daily administration
Study NCT00003746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-chlorodeoxyadenosine weekly
Description: Weekly administration
Study NCT00943059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
Study NCT00943059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cellulosum Mycrocryst
Description: Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
Study NCT03216889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
Study NCT03216889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
Study NCT04569266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercise rehabilitation treatment
Description: Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment).
Study NCT04569266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No specific exercise rehabilitation treatment
Description: Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment).
Study NCT03879707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Melatonin is known to induce sleep
Study NCT03879707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT03879707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium 500Mg Oral Tablet
Description: Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
Study NCT03468153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Description: Patient-derived dual specificity CD19 and CD22 CAR-T Cells
Study NCT02449655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Study NCT02449655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study NCT02449655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD2014
Description: AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
Study NCT02449655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study NCT02948972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete surgery
Description: complete surgery of colorectal deep infiltrating endometriosis
Study NCT02948972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In vitro fertilization without surgery
Description: IVF without endometriosis surgery
Study NCT02948972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro fertilization without surgery
Description: IVF without endometriosis surgery
Study NCT02906618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study NCT02906618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3C 15N 2H-LY3039478 IV
Description: Administered IV
Study NCT02370160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT2219ARL
Description: DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
Study NCT00823368 — intervention group
Intervention type: DRUG
Intervention: STX209
Study NCT00424840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m2
Description: Level II (every 21 day cycle, D8), 1.6 mg/m2
Study NCT00424840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.8 mg/m2
Description: Level III (every 21 day cycle, D8) 1.8 mg/m2
Study NCT00424840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: Carboplatin AUC6
Study NCT00424840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg
Study NCT03550001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection CNP before NAT
Description: Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
Study NCT02342639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg pills
Study NCT02342639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT03430388 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever vaccine (17D)
Description: Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI
Description: ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI matching placebo
Description: ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium matching placebo
Description: Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
Study NCT00424840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere 70 + G-CSF
Study NCT03688893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Application for Dental Bleaching
Description: The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
Study NCT02828995 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Diabetes Stigma Survey
Description: The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence.
Study NCT01801774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon 20-mg triamcinolone injection
Description: Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
Study NCT01801774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02749786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsy
Description: Skin biopsies will be performed via the Keys punch technique from normal facial skin.
Study NCT00744731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo for 1 week
Study NCT00744731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: 400 mg/day to 1,200 mg per day
Study NCT00509028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
Study NCT00509028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Asthma Therapy
Description: According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Study NCT02034864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
Study NCT02034864 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo of osteopathic manipulative treatment
Description: A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment.
Study NCT04241120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device and app system designed for participant to self-administer Habit Reversal Training
Description: Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
Study NCT04241120 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder bracelet control condition
Description: Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
Study NCT04459078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Intravenous administration of (200mg/3weeks)
Study NCT04459078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitacxel
Description: intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
Study NCT04459078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
Study NCT04457661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans TCI711
Description: Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
Study NCT00862498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Disclosure
Description: Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.